Whitehawk Therapeutics, Inc. WHWK
3.17 USD +0.07 (+2.26%)
At closeNov 4, 2026, 4:00 PM EST
3.17 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
3.11 Day range 3.33
1.97 52-week range 5.50
- YTD
- +30.99%
- 1 year
- +40.27%
- Market cap
- 180.72M
- EPS (ttm)
- -1.14
- YTD return
- +30.99%
- 1-year return
- +40.27%
- Volume
- 468.22K
- Avg volume
- 343.83K
- Open
- 3.22
- Previous close
- 3.10
- Day's range
- 3.11 – 3.33
- 52-week range
- 1.97 – 5.50
6M -1.04 (-24.70%)
Financials — quick view
WHWK Revenue — quarterly 0
WHWK Net income — quarterly -16.64M
WHWK EPS — quarterly -0.20
News
Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial Comparison 
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages 
Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16 
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 
Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9 
Analysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Price Target at $8.20 
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC 
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Your note
Sign in to keep a note on WHWK — it syncs with the Stock Master app.